Joann Scatina

Dr. Scatina brings more than 20 years of experience in preclinical development to Appello. Most recently, Scatina served as Senior Vice President of Preclinical Development at Lycera, a company focused on developing novel small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer.

She is also the former Vice President of Drug Metabolism at Wyeth Pharmaceuticals, where she led a team of up to 100 scientists, responsible for the preclinical development of marketed products including Premarin®, Duract®, Lodine®, Sonata®, Effexor®, Pristiq® and Rapamune® (1985 to 2001).

Dr. Scatina is currently serving on the editorial board of Drug Metabolism Reviews and has served as ad hoc reviewer for a number of drug metabolism journals. She is the associate editor for Drug Metabolism Handbook: Concepts and Applications. She is also a member of the Drug Discovery Advisory Group for the Polycystic Kidney Disease Foundation.